Nearly a quarter of patients who received Merck & Co’s immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a major medical meeting on Saturday.
Merck’s Keytruda sets new five-year survival standard for advanced lung cancer
More from Pharma NewsMore posts in Pharma News »
- Brazil coronavirus deaths climb to 46,510, cases near 1 million
- Requiring masks ‘political hazard’ as COVID-19 surges in California breadbasket
- Mothers as ‘trauma surgeons:’ the anguish of raising black boys in America
- Record spike in new coronavirus cases reported in six U.S. states as reopening accelerates